[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "POTUS, Pandemic is over", "description": "The pandemic is over (POTUS)\n\nhttps://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines\n\nEmergency use authorizations\n\nAugust 31, 2022\n\nhttps://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use\n\nToday, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna COVID-19 Vaccine,\n\nand the Pfizer-BioNTech COVID-19 Vaccine,\n\nto authorize bivalent formulations,\n\nfor use as a single booster dose\n\nOriginal strain + BA.4 and BA.5 lineages\n\nFor each bivalent COVID-19 vaccine, the FDA based its decision on the totality of available evidence, \n\nincluding extensive safety and effectiveness data for each of the monovalent mRNA COVID-19 vaccines, \n\nsafety and immunogenicity data obtained from a clinical study of a bivalent COVID-19 vaccine that contained mRNA from omicron variant BA.1 lineage\n\nthat is similar to each of the vaccines being authorized,\n\nBiden administration\n\nHas already placed an order for 170 million doses\n\nhttps://www.science.org/content/article/omicron-booster-shots-are-coming-lots-questions\n\nData collected by the companies\n\nHuman data, only available BA.1 booster\n\nBA.1 trails did not look for protection against severe disease, (People trials are very expensive)\n\nFor the BA.4/BA.5 boosters, the companies have submitted animal data. \n\n(not released publicly)\n\nPfizer presented preliminary findings in eight mice given BA.4/BA.5 vaccines as their third dose, (for EMA)\n\nShowed an increased antibody response to all Omicron variants tested: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5.\n\nClinical trials for the BA.4/BA.5 vaccines will begin this month\n\nAugust 19, 2022\n\nhttps://www.fda.gov/news-events/press-announcements/fda-roundup-august-19-2022\n\nToday, the FDA authorized the emergency use of Novavax COVID-19 Vaccine, \n\nin individuals 12 through 17 years of age. \n\nThis authorization follows a rigorous analysis and evaluation of the safety and effectiveness data conducted by the FDA. \n\nJuly 13, 2022\n\nhttps://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-emergency-use-novavax-covid-19-vaccine-adjuvanted\n\nToday, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the Novavax COVID-19 Vaccine, \n\nin individuals 18 years of age and older. \n\nJune 17, 2022\n\nhttps://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children\n\nToday, the U.S. Food and Drug Administration authorized emergency use of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine,\n\nin children down to 6 months of age.\n\nDecember 22, 2021\n\nhttps://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19\n\nToday, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer\u2019s Paxlovid", "link": "https://www.youtube.com/watch?v=MOM_nE-k3qo", "date_published": "2022-09-21 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]